← Leaderboards
Benjamin Matthew Segal
University Of Rochester
$9,506,634
Attributed
$9,506,634
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,506,634 · 9
VA$0 · 2
By mechanism
R01$9,049,239 · 7
R21$427,395 · 1
R13$30,000 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Multiple Sclerosis”
- David A. Hafler · Brigham And Women'S Hospital$33,720,341
- Vijay K Kuchroo · Brigham And Women'S Hospital$32,935,587
- Stephen L Hauser · University Of California San Francisco$32,469,388
- Katerina Akassoglou · University Of California San Diego$24,525,425
- Abdolmohamad Rostami · Thomas Jefferson University$23,969,638
- Stephen D Miller · Northwestern University$23,969,272
Research focus
Multiple SclerosisLeadBone MarrowInflammatoryCellsNeuraxisPropertyMyelinDisabilityPreventAnimal ModelPhenotypeChronicNeurologicMonocyteExperimental Autoimmune EncephalomyelitisRelapseMediatingMicrogliaRepairedAutoimmune ProcessSignal TransductionAdoptive TransferAxon
Grant awards (41)
Enhancement of RGC survival and Optic Nerve Regeneration by Cytokine Polarized Myeloid Cells$665,243
R01 · FY2025 · EY · contact PI
A novel inflammatory cell with neuroprotective and neuroregenerative properties$263,620
R01 · FY2022 · EY · contact PI
FASEB SRC: The Translational Neuroimmunology Conference: From Bench to Bedside and Back$30,000
R13 · FY2022 · NS · contact PI
Arginase-1 and iNOS expressing CNS myeloid cell subsets in EAE and MS$357,525
R01 · FY2021 · NS · contact PI
A novel inflammatory cell with neuroprotective and neuroregenerative properties$267,068
R01 · FY2021 · EY · contact PI
Immune mediated regeneration of retinal ganglion cell axons following optic nerve trauma$357,904
R01 · FY2020 · EY · contact PI
Arginase-1 and iNOS expressing CNS myeloid cell subsets in EAE and MS$357,525
R01 · FY2020 · NS · contact PI
A novel inflammatory cell with neuroprotective and neuroregenerative properties$278,809
R01 · FY2020 · EY · contact PI
Immune mediated regeneration of retinal ganglion cell axons following optic nerve trauma$374,224
R01 · FY2019 · EY · contact PI
Arginase-1 and iNOS expressing CNS myeloid cell subsets in EAE and MS$357,525
R01 · FY2019 · NS · contact PI
A novel inflammatory cell with neuroprotective and neuroregenerative properties$209,542
R01 · FY2019 · EY · contact PI
A novel inflammatory cell with neuroprotective and neuroregenerative properties$102,458
R01 · FY2019 · EY · contact PI
Arginase-1 and iNOS expressing CNS myeloid cell subsets in EAE and MS$426,409
R01 · FY2018 · NS · contact PI
Immune mediated regeneration of retinal ganglion cell axons following optic nerve trauma$390,000
R01 · FY2018 · EY · contact PI
A novel inflammatory cell with neuroprotective and neuroregenerative properties$311,503
R01 · FY2018 · EY · contact PI
The mechanism of action of Granulocyte Macrophage-Colony Stimulating Factor in an animal model of Multiple Sclerosis$194,895
R21 · FY2018 · NS · contact PI
Arginase-1 and iNOS expressing CNS myeloid cell subsets in EAE and MS$438,329
R01 · FY2017 · NS · contact PI
Immune mediated regeneration of retinal ganglion cell axons following optic nerve trauma$387,917
R01 · FY2017 · EY · contact PI
The mechanism of action of Granulocyte Macrophage-Colony Stimulating Factor in an animal model of Multiple Sclerosis$232,500
R21 · FY2017 · NS · contact PI
Nogo Receptors as Therapeutic Targets in a Model of Multiple Sclerosis$0
I01 · FY2016 · VA · contact PI
Preclinical studies of a MADCAM-Fc fusion protein in multiple sclerosis$0
I01 · FY2015 · VA · contact PI
Nogo Receptors as Therapeutic Targets in a Model of Multiple Sclerosis$0
I01 · FY2015 · VA · contact PI
The regulation of myeloid cell development and mobilization during autoimmune dem$252,626
R01 · FY2014 · NS · contact PI
Preclinical studies of a MADCAM-Fc fusion protein in multiple sclerosis$0
I01 · FY2014 · VA · contact PI
Preclinical studies of a MADCAM-Fc fusion protein in multiple sclerosis$0
I01 · FY2014 · VA · contact PI
Nogo Receptors as Therapeutic Targets in a Model of Multiple Sclerosis$0
I01 · FY2014 · VA · contact PI
The regulation of myeloid cell development and mobilization during autoimmune dem$246,522
R01 · FY2013 · NS · contact PI
Nogo Receptors as Therapeutic Targets in a Model of Multiple Sclerosis$0
I01 · FY2013 · VA · contact PI
The regulation of myeloid cell development and mobilization during autoimmune dem$255,739
R01 · FY2012 · NS · contact PI
Preclinical studies of a MADCAM-Fc fusion protein in multiple sclerosis$0
I01 · FY2012 · VA · contact PI
The regulation of myeloid cell development and mobilization during autoimmune dem$256,008
R01 · FY2011 · NS · contact PI
The regulation of myeloid cell development and mobilization during autoimmune dem$261,498
R01 · FY2010 · NS · contact PI
Lymphoid Chemokines in Autoimmune Encephalomyelitis$292,149
R01 · FY2007 · NS · contact PI
Lymphoid Chemokines in Autoimmune Encephalomyelitis$15,701
R01 · FY2007 · NS · contact PI
Lymphoid Chemokines in Autoimmune Encephalomyelitis$317,045
R01 · FY2006 · NS · contact PI
Lymphoid Chemokines in Autoimmune Encephalomyelitis$324,675
R01 · FY2005 · NS
Lymphoid Chemokines in Autoimmune Encephalomyelitis$324,675
R01 · FY2004 · NS
CYTOKINE REGULATION OF MATURE MYELIN-SPECIFIC T CELLS$239,250
R01 · FY2004 · NS
CYTOKINE REGULATION OF MATURE MYELIN-SPECIFIC T CELLS$239,250
R01 · FY2003 · NS
CYTOKINE REGULATION OF MATURE MYELIN-SPECIFIC T CELLS$239,250
R01 · FY2002 · NS
CYTOKINE REGULATION OF MATURE MYELIN-SPECIFIC T CELLS$239,250
R01 · FY2001 · NS